Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mike Keymer"'
Autor:
David L. Ennist, Erik P. Pioro, Stephen Apple, Benjamin Rix Brooks, Albert A. Taylor, Mike Keymer, Mark Schactman, Johnna Perdrizet, Danielle Beaulieu, Wendy Agnese
Publikováno v:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 23:49-57
Introduction: The edaravone development program for amyotrophic lateral sclerosis (ALS) included trials MCI186-16 (Study 16) and MCI186-19 (Study 19). A cohort enrichment strategy was based on a Study 16 post hoc analysis and applied to Study 19 to e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cecd240116f16610dd21acdf09cc8fe
https://doi.org/10.1080/21678421.2021.1927102
https://doi.org/10.1080/21678421.2021.1927102
Autor:
Karen Aboody, Olubankole Aladesuyi Arogundade, Giovanni Appendino, Weiqi Bao, Marco A.S. Baptista, Danielle Beaulieu, Frank Bennett, Emma Brand, Don Cleveland, Stanley L. Cohan, Jonavelle Cuerdo, Jim DeMesa, David L. Ennist, Meryem Guler, Nada Hindiyeh, Hanna Hovren, Yiyun Henry Huang, Hongmei Jia, Jie Jiang, Brian K. Kaspar, Petra Kaufmann, Randall Kaye, Jeffery W. Kelly, Mike Keymer, Doo Yeon Kim, Kiren Kresa-Reahl, Ikjae Lee, Melanie Leitner, Stefanie N. Linch, Elisabeth B. Lucassen, Timothy Miller, Rachael Mooney, Gaetano Morello, Eduardo Muñoz, Michael Murray, Hoi Wa Ngai, Joseph Park, Dustin Pierce, Jana Portnow, Evan T. Powers, Luisa Quinti, John Ravits, Meghan Romba, Rajesh Sampath, S. Pablo Sardi, Mark Schactman, Mohammad Shahnawaz, Richard A. Smith, Kyle E. Smoot, Claudio Soto, Clive N. Svendsen, Soshana P. Svendsen, Rudolph E. Tanzi, Albert A. Taylor, Gil I. Wolfe, Clinton B. Wright, Gerald Yakatan, Neta Zach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc3421a84af02dbf2e438ec95985c79e
https://doi.org/10.1016/b978-0-12-816475-4.09992-4
https://doi.org/10.1016/b978-0-12-816475-4.09992-4
Autor:
Mike Keymer, David L. Ennist, Mark Schactman, Danielle Beaulieu, Dustin Pierce, Albert A. Taylor, Jonavelle Cuerdo
Neurological and neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS), are characterized by heterogeneous disease progression. As a group, these complex disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9e79bcc8d597d71723dc6f8b89a5d3a
https://doi.org/10.1016/b978-0-12-816475-4.00005-7
https://doi.org/10.1016/b978-0-12-816475-4.00005-7
Autor:
James D. Berry, David L. Ennist, Lisa Meng, Mike Keymer, Albert A. Taylor, Danielle Beaulieu, Amy Bian, Bernard Ravina, Jinsy A. Andrews
Publikováno v:
Annals of Clinical and Translational Neurology
Introduction In small trials, randomization can fail, leading to differences in patient characteristics across treatment arms, a risk that can be reduced by stratifying using key confounders. In ALS trials, riluzole use (RU) and bulbar onset (BO) hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb10811554a3b05fe9172fe60de42da
https://doi.org/10.1002/acn3.550
https://doi.org/10.1002/acn3.550
Autor:
Jinsy A. Andrews, Lisa Meng, Mike Keymer, Samad Jahandideh, David L. Ennist, Nazem Atassi, Danielle Beaulieu, Albert A. Taylor, Amy Bian
Publikováno v:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 19:294-302
Death in amyotrophic lateral sclerosis (ALS) patients is related to respiratory failure, which is assessed in clinical settings by measuring vital capacity. We developed ALS-VC, a modeling tool for longitudinal prediction of vital capacity in ALS pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc25dd4e71f90998588101b4057cb77b
https://doi.org/10.1080/21678421.2017.1418003
https://doi.org/10.1080/21678421.2017.1418003
Autor:
Christina Fournier, Neta Zach, Liuxia Wang, Meraida Polak, David L. Ennist, Jonathan D. Glass, Albert A. Taylor, Mike Keymer
Publikováno v:
Annals of Clinical and Translational Neurology
Objective It is essential to develop predictive algorithms for Amyotrophic Lateral Sclerosis (ALS) disease progression to allow for efficient clinical trials and patient care. The best existing predictive models rely on several months of baseline dat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c97074d227112625049754053c702f89
https://doi.org/10.1002/acn3.348
https://doi.org/10.1002/acn3.348